Epigenetic modulation of antitumor immunity for improved cancer immunotherapy DOI Creative Commons
Enyong Dai, Zhi Zhu,

Shudipto Wahed

et al.

Molecular Cancer, Journal Year: 2021, Volume and Issue: 20(1)

Published: Dec. 20, 2021

Abstract Epigenetic mechanisms play vital roles not only in cancer initiation and progression, but also the activation, differentiation effector function(s) of immune cells. In this review, we summarize current literature related to epigenomic dynamics cells impacting cell fate functionality, immunogenicity Some important immune-associated genes, such as granzyme B, IFN-γ, IL-2, IL-12, FoxP3 STING, are regulated via epigenetic or/and cells, checkpoint molecules (PD-1, CTLA-4, TIM-3, LAG-3, TIGIT) expressed by tumor-associated stromal Thus, therapeutic strategies implementing modulating drugs expected significantly impact tumor microenvironment (TME) promoting transcriptional metabolic reprogramming local populations, resulting inhibition immunosuppressive (MDSCs Treg) activation anti-tumor T professional antigen presenting (APC), well which can serve non-professional APC. latter instance, agents may coordinately promote inducing de novo expression transcriptionally repressed antigens, increasing neoantigens MHC processing/presentation machinery, activating immunogenic death (ICD). ICD provides a rich source immunogens for cross-priming sensitizing interventional immunotherapy. way, modulators be envisioned effective components combination immunotherapy approaches capable mediating superior efficacy.

Language: Английский

Macrophages and Metabolism in the Tumor Microenvironment DOI Creative Commons
Ilio Vitale, Gwenola Manic, Lisa M. Coussens

et al.

Cell Metabolism, Journal Year: 2019, Volume and Issue: 30(1), P. 36 - 50

Published: July 1, 2019

Language: Английский

Citations

1345
Autophagy in major human diseases DOI Creative Commons
Daniel J. Klionsky, Giulia Petroni, Ravi K. Amaravadi

et al.

The EMBO Journal, Journal Year: 2021, Volume and Issue: 40(19)

Published: Aug. 30, 2021

Review30 August 2021Open Access Autophagy in major human diseases Daniel J Klionsky orcid.org/0000-0002-7828-8118 Life Sciences Institute, University of Michigan, Ann Arbor, MI, USA Search for more papers by this author Giulia Petroni Department Radiation Oncology, Weill Cornell Medical College, New York, NY, Ravi K Amaravadi Medicine, Pennsylvania, Philadelphia, PA, Abramson Cancer Center, Eric H Baehrecke Molecular, Cell and Biology, Massachusetts School, Worcester, MA, Andrea Ballabio orcid.org/0000-0003-1381-4604 Telethon Institute Genetics Pozzuoli, Italy Translational Sciences, Section Pediatrics, Federico II University, Naples, Molecular Human Genetics, Baylor College Jan Dan Duncan Neurological Research Texas Children Hospital, Houston, TX, Patricia Boya orcid.org/0000-0003-3045-951X Margarita Salas Center Biological Research, Spanish National Council, Madrid, Spain José Manuel Bravo-San Pedro Faculty Physiology, Complutense Networked Biomedical Neurodegenerative Diseases (CIBERNED), Ken Cadwell Kimmel Biology Medicine at the Skirball York Grossman School Microbiology, Division Gastroenterology Hepatology, Langone Health, Francesco Cecconi orcid.org/0000-0002-5614-4359 Stress Survival Unit, Autophagy, Recycling Disease (CARD), Danish Society Copenhagen, Denmark Pediatric Onco-Hematology Gene Therapy, IRCCS Bambino Gesù Children's Rome, Rome 'Tor Vergata', Augustine M Choi Pulmonary Critical Care Joan Sanford I. York-Presbyterian Mary E Nephrology Hypertension, Charleen T Chu orcid.org/0000-0002-5052-8271 Pathology, Pittsburgh Pittsburgh, Patrice Codogno orcid.org/0000-0002-5492-3180 Institut Necker-Enfants Malades, INSERM U1151-CNRS UMR 8253, Paris, France Université de Maria Isabel Colombo Laboratorio Mecanismos Moleculares Implicados en el Tráfico Vesicular y la Autofagia-Instituto Histología Embriología (IHEM)-Universidad Nacional Cuyo, CONICET- Facultad Ciencias Médicas, Mendoza, Argentina Ana Cuervo orcid.org/0000-0002-0771-700X Developmental Albert Einstein Bronx, Aging Studies, Vojo Deretic Inflammation Metabolism (AIM, Excellence, Mexico Health Albuquerque, NM, Ivan Dikic orcid.org/0000-0001-8156-9511 Biochemistry II, Goethe Frankfurt, Frankfurt am Main, Germany Buchmann Zvulun Elazar Biomolecular The Weizmann Science, Rehovot, Israel Eeva-Liisa Eskelinen Biomedicine, Turku, Finland Gian Fimia orcid.org/0000-0003-4438-3325 Sapienza Epidemiology, Preclinical Advanced Diagnostics, Infectious 'L. Spallanzani' IRCCS, David A Gewirtz orcid.org/0000-0003-0437-4934 Pharmacology Toxicology, Virginia Commonwealth Richmond, VA, Douglas R Green Immunology, St. Jude Memphis, TN, Malene Hansen Burnham Prebys Discovery Program Development, Aging, Regeneration, La Jolla, CA, Marja Jäättelä orcid.org/0000-0001-5950-7111 Death Metabolism, & Disease, Cellular Terje Johansen orcid.org/0000-0003-1451-9578 Group, Tromsø—The Arctic Norway, Tromsø, Norway Gábor Juhász Szeged, Hungary Anatomy, Eötvös Loránd Budapest, Vassiliki Karantza Merck Co., Inc., Kenilworth, NJ, Claudine Kraft orcid.org/0000-0002-3324-4701 ZBMZ, Freiburg, CIBSS - Centre Integrative Signalling Guido Kroemer orcid.org/0000-0002-9334-4405 Recherche des Cordeliers, Equipe Labellisée par Ligue Contre le Cancer, Sorbonne Université, Inserm U1138, Universitaire France, Metabolomics Platforms, Gustave Roussy, Villejuif, Pôle Biologie, Hôpital Européen Georges Pompidou, AP-HP, Suzhou Systems Chinese Academy Suzhou, China Karolinska Women's Stockholm, Sweden Nicholas Ktistakis Programme, Babraham Cambridge, UK Sharad Kumar orcid.org/0000-0001-7126-9814 South Australia, Adelaide, SA, Australia Carlos Lopez-Otin orcid.org/0000-0001-6964-1904 Departamento Bioquímica Biología Medicina, Instituto Universitario Oncología del Principado Asturias (IUOPA), Universidad Oviedo, Centro Investigación Biomédica Red Cáncer (CIBERONC), Kay F Macleod Ben May Gordon W-338, Chicago, IL, Frank Madeo Biosciences, NAWI Graz, Austria BioTechMed-Graz, Field Excellence BioHealth – Jennifer Martinez Immunity, Laboratory, Environmental NIH, Triangle Park, NC, Alicia Meléndez Department, Queens City Flushing, Graduate PhD Programs Noboru Mizushima orcid.org/0000-0002-6258-6444 Tokyo, Japan Christian Münz orcid.org/0000-0001-6419-1940 Viral Immunobiology, Experimental Zurich, Switzerland Josef Penninger Biotechnology Austrian (IMBA), Vienna BioCenter (VBC), Vienna, British Columbia, Vancouver, BC, Canada Rushika Perera orcid.org/0000-0003-2435-2273 California, San Francisco, Helen Diller Family Comprehensive Mauro Piacentini orcid.org/0000-0003-2919-1296 "Tor Vergata", Laboratory Cytology Russian Saint Petersburg, Russia Fulvio Reggiori orcid.org/0000-0003-2652-2686 Cells Systems, Section, Groningen, Netherlands C Rubinsztein Cambridge Dementia Kevin Ryan Beatson Glasgow, Junichi Sadoshima Cardiovascular Rutgers Jersey Newark, Laura Santambrogio Sandra Edward Meyer Caryl Englander Precision Luca Scorrano orcid.org/0000-0002-8515-8928 Istituto Veneto di Medicina Molecolare, Padova, Hans-Uwe Simon Pharmacology, Bern, Clinical Immunology Allergology, Sechenov Moscow, Fundamental Kazan Federal Kazan, Anna Katharina Kennedy Rheumatology, NDORMS, Oxford, Anne Simonsen orcid.org/0000-0003-4711-7057 Basic Oslo, Reprogramming, Oslo Hospital Montebello, Alexandra Stolz orcid.org/0000-0002-3340-439X Nektarios Tavernarakis orcid.org/0000-0002-5253-1466 Biotechnology, Foundation Technology-Hellas, Heraklion, Crete, Greece Sharon Tooze orcid.org/0000-0002-2182-3116 Francis Crick London, Tamotsu Yoshimori orcid.org/0000-0001-9787-3788 Osaka Suita, Intracellular Membrane Dynamics, Frontier Integrated Science Division, Open Transdisciplinary Initiatives (OTRI), Junying Yuan Interdisciplinary on Chemistry, Shanghai Organic Shanghai, Harvard Boston, Zhenyu Yue Neurology, Friedman Brain Icahn Mount Sinai, Qing Zhong orcid.org/0000-0001-6979-955X Key Differentiation Apoptosis Ministry Education, Pathophysiology, Jiao Tong (SJTU-SM), Lorenzo Galluzzi Corresponding Author [email protected] orcid.org/0000-0003-2257-8500 Dermatology, Yale Haven, CT, Pietrocola orcid.org/0000-0002-2930-234X Biosciences Nutrition, Huddinge, mor

Language: Английский

Citations

1096
Immunogenic cell stress and death DOI Open Access
Guido Kroemer,

Claudia Galassi,

Laurence Zitvogel

et al.

Nature Immunology, Journal Year: 2022, Volume and Issue: 23(4), P. 487 - 500

Published: Feb. 10, 2022

Language: Английский

Citations

863
Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease DOI
Dominic P. Del Re, Dulguun Amgalan, Andreas Linkermann

et al.

Physiological Reviews, Journal Year: 2019, Volume and Issue: 99(4), P. 1765 - 1817

Published: July 31, 2019

Twelve regulated cell death programs have been described. We review in detail the basic biology of nine including receptor-mediated apoptosis, necrosis (necroptosis), mitochondrial-mediated necrosis, autophagy-dependent death, ferroptosis, pyroptosis, parthanatos, and immunogenic death. This is followed by a dissection roles these major cardiac syndromes: myocardial infarction heart failure. The most important conclusion relevant to disease that forms cardiomyocyte play both with reperfusion (ischemia/reperfusion) While role for apoptosis ischemia/reperfusion cannot be excluded, through receptor mitochondrial pathways, are critical. Ferroptosis parthanatos also likely ischemia/reperfusion, although it unclear if entities functioning as independent or amplification mechanisms necrotic Pyroptosis may contribute injury, but potentially effects non-cardiomyocytes. Cardiomyocyte loss an component pathogenesis failure mediated signaling. Roles remain defined merit study this era immune checkpoint cancer therapy. Biology-based approaches inhibit various syndromes discussed.

Language: Английский

Citations

751
Targeting tumor-associated macrophages to synergize tumor immunotherapy DOI Creative Commons
Xiaonan Xiang, Jianguo Wang, Di Lu

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2021, Volume and Issue: 6(1)

Published: Feb. 23, 2021

Abstract The current treatment strategies in advanced malignancies remain limited. Notably, immunotherapies have raised hope for a successful control of these diseases, but their therapeutic responses are suboptimal and vary considerably among individuals. Tumor-associated macrophages (TAMs) major component the tumor microenvironment (TME) often correlated with poor prognosis therapy resistance, including immunotherapies. Thus, deeper understanding complex roles TAMs immunotherapy regulation could provide new insight into TME. Furthermore, targeting is an emerging field interest due to that will synergize In this review, we summarize recent studies investigating involvement immune checkpoint inhibition, vaccines adoptive cell transfer therapies, discuss potential as adjuvant

Language: Английский

Citations

605
Intratumoral heterogeneity in cancer progression and response to immunotherapy DOI
Ilio Vitale, Efrat Shema, Sherene Loi

et al.

Nature Medicine, Journal Year: 2021, Volume and Issue: 27(2), P. 212 - 224

Published: Feb. 1, 2021

Language: Английский

Citations

578
Engineering nanomedicine for glutathione depletion-augmented cancer therapy DOI
Yuxuan Xiong, Chen Xiao, Zifu Li

et al.

Chemical Society Reviews, Journal Year: 2021, Volume and Issue: 50(10), P. 6013 - 6041

Published: Jan. 1, 2021

In this review, we systematically survey the most recent progress in engineering nanomedicine for intracellular glutathione consumption-augmented cancer therapy.

Language: Английский

Citations

525
Cancer stem cell–immune cell crosstalk in tumour progression DOI
Defne Bayık, Justin D. Lathia

Nature reviews. Cancer, Journal Year: 2021, Volume and Issue: 21(8), P. 526 - 536

Published: June 8, 2021

Language: Английский

Citations

383
Recent advances in nanomaterial-based synergistic combination cancer immunotherapy DOI
Wei Sang, Zhan Zhang, Yunlu Dai

et al.

Chemical Society Reviews, Journal Year: 2019, Volume and Issue: 48(14), P. 3771 - 3810

Published: Jan. 1, 2019

This review aims to summarize various synergistic combination cancer immunotherapy strategies based on nanomaterials.

Language: Английский

Citations

349
Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology DOI Creative Commons
Keman Cheng, Ruifang Zhao, Yao Li

et al.

Nature Communications, Journal Year: 2021, Volume and Issue: 12(1)

Published: April 6, 2021

An effective tumor vaccine vector that can rapidly display neoantigens is urgently needed. Outer membrane vesicles (OMVs) strongly activate the innate immune system and are qualified as immunoadjuvants. Here, we describe a versatile OMV-based platform to elicit specific anti-tumor response via specifically presenting antigens onto OMV surface. We first on OMVs surface by fusing with ClyA protein, then simplify antigen process employing Plug-and-Display comprising tag/catcher protein pairs. decorated different catchers simultaneously multiple, distinct synergistic antitumour response. In addition, bioengineered loaded abrogate lung melanoma metastasis inhibit subcutaneous colorectal cancer growth. The ability of may facilitate development these agents for personalized tumour vaccines.

Language: Английский

Citations

331